Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Piramal Pharma Limited ( (IN:PPLPHARMA) ) has provided an update.
Piramal Pharma’s step-down wholly owned subsidiary, Piramal Critical Care B.V., has signed definitive agreements to acquire Kenalog and associated injectable corticosteroid brands from Bristol-Myers Squibb for an upfront US$35 million, plus up to US$65 million in contingent payments tied to operational and financial milestones, subject to closing conditions. The acquisition of Kenalog, which is marketed under multiple trademarks in 15 countries and indicated for various inflammatory conditions, is set to deepen Piramal Pharma’s portfolio of hospital-focused injectable products and is expected to enhance growth by leveraging its global hospital distribution network, particularly strengthening its presence and future revenue potential in the US, Europe and Asia-Pacific, without involving any related-party transactions.
More about Piramal Pharma Limited
Piramal Pharma Limited, through its subsidiary Piramal Critical Care B.V., operates in the pharmaceutical industry with a focus on branded and specialty injectable products. The company leverages an extensive global distribution network reaching more than 6,000 hospitals across over 100 countries, with key markets including the US, Europe and Asia-Pacific.
Average Trading Volume: 222,676
Technical Sentiment Signal: Sell
Current Market Cap: 201.2B INR
Learn more about PPLPHARMA stock on TipRanks’ Stock Analysis page.